A 50-year-old patient battling life-threatening Castleman’s disease was offered Adalimumab as last-line therapy after identification of adalimumab by AI-based discovery.
Every Cure and its partners are extending this discovery with new AI algorithms that calculate the potential dosage of any drug to treat any disease. Initial promising candidates for further research include bosutinib for ALS, metreleptin for anorexia, and folinic acid for autism spectrum disorders.
Philadelphia, July 13, 2023 /PRNewswire/ — Lab researchers save patient’s life University of Pennsylvaniathe Castleman Disease Collaborative Network, Medidata, a Dassault Systèmes company, and Every Cure, led by Dr. David Fazimbaumused AI to uncover a previously unknown use of the existing drug adalimumab to treat idiopathic multicentric Castleman disease (iMCD). Every Cure and its partners are developing medical databases and AI algorithms to explore new uses for existing medicines across all diseases, with the latest scoring showing that out of all 3,000 approved medicines: Adalimumab has been identified as the most promising treatment for iMCD.
iMCD is a rare and life-threatening disease that involves over-activation of the body’s immune system leading to uncontrolled organ dysfunction. The only FDA-approved treatment works for some patients diagnosed with iMCD, leaving the majority of patients with limited options. Her 50-year-old iMCD patient Albert, who had exhausted all known treatments, was prescribed adalimumab by her doctor. Luke Chen from University of British Columbia After consulting with Dr. Fajgenbaum of Every Cure and his team, who used an AI-guided proteomics approach to identify the drug’s potential benefits,
“Unfortunately, after a two-year battle with iMCD, I was left with no other options and my family and I were preparing for hospice care,” Albert said. The Every Cure team identified this treatment just as Albert was beginning to show the worst symptoms in his two-year battle with iMCD. Within days of taking adalimumab, his organs regained function and his symptoms subsided and he was in remission. The use of adalimumab to treat iMCD would represent a novel application.
Adalimumab is a monoclonal antibody commonly used to treat serious and often life-threatening inflammatory diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and Crohn’s disease. It is administered by subcutaneous injection. Adalimumab was first approved by the US Food and Drug Administration (FDA) in 2002. Treatment of iMCD with adalimumab is not currently an approved use. With this breakthrough discovery, Every Cure and its research partners are beginning to lay the groundwork for conducting clinical trials to further validate its use in iMCD.
To extend this case study to other potential uses, Every Cure, a non-profit organization dedicated to maximizing the potential of approved medicines to treat additional diseases: University of Pennsylvania, Pennsylvania State Universityand the University of North Carolinainclude David Koslicski, Alex Tropsiaand Chris Bizon AI-powered Every Cure Link Map. The algorithm scores the potential of existing drugs to treat any known disease based on global knowledge from publications and databases.of Every Cure Link Map was the first to rank all 3,000 drugs approved by the FDA to treat all 12,000 human ailments, generating 36 million reviews. Every Cure is currently analyzing the top results from the initial survey results. all treatments link map, In addition to consulting industry experts, identify the most promising candidates for repurposing, including opportunities such as metreleptin for anorexia, folinic acid for autism spectrum disorders, anakinra for sepsis, and bosutinib for ALS use To do. These candidates and others will be further evaluated and prioritized for future clinical trials.
Every Cure is a non-profit organization seeking immediate funding to further optimize the algorithm and evaluate the best ranked results directly to patients. We are also seeking partnerships for data contributions. “We are extremely grateful for the progress we have made with limited resources that have already saved the lives of patients diagnosed with Castleman disease, angiosarcoma and COVID-19 by repurposing existing medicines. is encouraged,” said Every Cure’s co-founder and CEO. Grant Mitchell. “But as we integrate more data, optimize our algorithms, and explore the most promising leads, we are even more excited about the potential impact of the future. “It’s about providing choice to patients who have been diagnosed with cancer, and that’s what we’re going to do.” is sorely needed and we are in a position to do it.”
Co-Founder of Every Cure and Director of the Cytokine Storm Center for Treatment and Testing (CSTL) Dr. David Fazimbaumannounced this important advance at the 2019 STAT Summit. San Francisco.
“I live on a repurposed medicine I discovered when I was dying of a rare disease during medical school. Now I unlock every cure, every cure when sick We’re on a mission to make sure no patient says they’ve tried it, and there are life-saving treatments on pharmacy shelves,” said Dr Fagenbaum.
Contact us for more information or to express your interest in partnering with Every Cure. Brent Shaw ([email protected]818-876-2691).
You can read the full story of Al’s journey here.
for any treatment
all treatments is a non-profit organization dedicated to unlocking the full potential of every existing medicine to treat every disease. Repurposing existing drugs is the quickest and most efficient way to treat disease and offers the greatest return on investment in saving lives. However, patients suffer from underutilization of potential therapies because systemic barriers prevent reuse. Every Cure overcomes these barriers, systematically identifying and promoting promising reuse opportunities to save lives. Every Cure will generate these systematic data by developing a comprehensive open source data engine to generate predictive efficacy scores for all 3,000 drugs for all 12,000 diseases and expedite patient care. We employ innovative and disruptive approaches to overcome barriers. Every Cure partners with academia, industry and government to integrate proprietary and public data into comprehensive datasets, optimize AI ranking algorithms, validate the most promising drug-disease matches, We conduct clinical trials to ensure patient access to effective treatments. Every Cure announced the launch of his September 2022 At the Clinton Global Initiative.
For more information, visit EveryCure.org or contact us here. twitter, LinkedIn, Facebookand Instagram.
About the Founder of Every Cure
Doctor. David Fazimbaumco-founder of Every Cure
David FazimbaumM.D., M.B.A., M.S., and is a physician and scientist. University of Pennsylvaniaco-founder of Every Cure, co-founder and president of the Castleman Disease Collaborative Network, and author of the national bestseller “Chasing” my cure: A race for doctors to put their hopes into action. He is also a patient battling a deadly disease called idiopathic multicentric Castleman disease (iMCD) and has found a cure for it, saving his and others’ lives. through his work of the University of Pennsylvania At the Cytokine Storm Treatment and Research Center, he has also identified and promoted 14 other therapeutic approaches for iMCD and cancer. He also serves on the board of the FDA’s Reagan-Udall Foundation. Fajgenbaum has published scientific papers in high-impact journals such as the New England Journal of Medicine, the Journal of Clinical Investigation and The Lancet, has received awards such as the 2016 Atlas Award, and was the Vice President at the time. was awarded with Joe Bidenprofiled with. new york times cover story and Good morning, America, CNN, Forbes 30 Under 30and the today’s show. Dr. Fazimbaum Georgetown Universitymaster’s degree oxford universityfrom Doctor of Medicine University of Pennsylvaniaobtained an MBA from the Wharton School.
Doctor. Grant MitchellCo-founder and CEO of Every Cure
Grant Mitchell, MD, MBA, co-founder and CEO of Every Cure. He is an experienced entrepreneur, manager and investor in the fields of health, technology and machine learning. He has launched multiple healthtech companies and has held his CEO role in life sciences and technology organizations. Dr. Mitchell previously served as Principal in Analytics at QuantumBlack, the artificial intelligence division of McKinsey & Company. There, he led a team that pioneered the use of machine learning algorithms and real-world evidence databases to predict health outcomes for subpopulations by drug class. Dr. Mitchell has been integral to the effort to support Dr. Feigenbaum in his quest for a cure for his rare disease, and he also collaborated with Dr. Feigenbaum on the CORONA project. Every Cure is the culmination of Dr. Mitchell and Dr. Fagenbaum’s experience in rare disease research, drug repurposing, and advanced analytics. Dr. Mitchell holds a BA in Economics. new york universityfrom Doctor of Medicine University of Pennsylvaniaobtained an MBA from the Wharton School.
Tracy Sikoraco-founder of Every Cure
Tracy Sikora Researched repurposed drugs in rare diseases. Niemann pick C, MPS I, familial hypercholesterolemia, etc. She has led clinical trials working with partners in biotechnology companies and rare disease organizations to develop research protocols that are adaptable to the challenging realities of conducting clinical studies in the real world. Inspired by a groundbreaking clinical trial launched for COVID-19 research, Tracy brings to the team a bold plan for an efficient and well-executed clinical trial. I’m here.Tracy is getting her BS Cornell University.
About the Castleman’s Disease Collaborative Network
of Castleman’s Disease Collaborative Network (CDCN) is a global non-profit organization dedicated to advancing research, therapy and patient care. Castleman disease (CD) is a rare and highly fatal disease with a wide spectrum of autoimmune and cancer-like symptoms. CDCN’s groundbreaking approach includes a highly collaborative research model and an approach focused on repurposing existing drugs approved for other diseases, which will help thousands of people. lives have been saved and has become a gold standard for rare disease research. This organization was founded in 2012. David FazimbaumMD, MBA, MSc, FCPPand fritz van leeDoctor of Medicine, Ph.D.is based on University of PennsylvaniaThere, Dr. Feigenbaum, a physician, scientist, and CD patient, makes it his lifelong mission to revolutionize biomedical research to cure this disease and countless other ailments. . For more information, please refer to the following URL: cdcn.org.
Source All Treatments
